CLINICAL TRIALS PROFILE FOR MEXITIL

All Clinical Trials for MEXITIL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01849770 ↗	Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)	Completed	University of Washington	Phase 2	2013-07-01	The purpose of this research is to find out if mexiletine is safe and effective in people with Amyotrophic Lateral Sclerosis (ALS). In this trial, participants will be taking either 300 milligrams per day of mexiletine, 900 milligrams per day of mexiletine or placebo (non-active study drug). The safety and efficacy of these doses will be compared to see if one dose is better than the other.
NCT02045667 ↗	Combined N-of-1 Trials Mexiletine vs Placebo in Patients With Non-Dystrophic Myotonia (NDM)	Completed	ZonMw: The Netherlands Organisation for Health Research and Development	Phase 2	2014-01-01	The main objective of this study is to explore whether multiple trials with individual patients (N-of-1 trials) can produce a reliable evidence base for coverage decisions on clinical and cost-effectiveness of drug treatment for patients with rare diseases. As a case study, we will study the clinical and cost-effectiveness of Mexiletine in patients with Non-Dystrophic myotonia. The results of this analysis will be compared with the results obtained from a recently published international, multi-centre, randomized, placebo-controlled trial of Mexiletine in patients with Non-Dystrophic Myotonia (clinicaltrials.gov Identifier: NCT00832000). The secondary objective of this proposal is to assess whether mexiletine improves myotonia measured (both quantitatively and qualitative) in patients with non-dystrophic myotonia.
NCT02045667 ↗	Combined N-of-1 Trials Mexiletine vs Placebo in Patients With Non-Dystrophic Myotonia (NDM)	Completed	Radboud University	Phase 2	2014-01-01	The main objective of this study is to explore whether multiple trials with individual patients (N-of-1 trials) can produce a reliable evidence base for coverage decisions on clinical and cost-effectiveness of drug treatment for patients with rare diseases. As a case study, we will study the clinical and cost-effectiveness of Mexiletine in patients with Non-Dystrophic myotonia. The results of this analysis will be compared with the results obtained from a recently published international, multi-centre, randomized, placebo-controlled trial of Mexiletine in patients with Non-Dystrophic Myotonia (clinicaltrials.gov Identifier: NCT00832000). The secondary objective of this proposal is to assess whether mexiletine improves myotonia measured (both quantitatively and qualitative) in patients with non-dystrophic myotonia.
NCT02308748 ↗	Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block	Completed	Spaulding Clinical Research LLC	Phase 1	2014-05-01	The primary objective of this research study is to test the hypothesis that late sodium current blocking drugs (mexiletine or lidocaine) can attenuate the effect of hERG potassium channel blocking drugs (dofetilide) on ventricular repolarization (QTc) by shortening early repolarization (J-Tpeakc). The secondary object is to assess the ability of calcium channel block (diltiazem) to reduce the QTc prolongation associated with hERG block (moxifloxacin).
NCT02308748 ↗	Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block	Completed	Food and Drug Administration (FDA)	Phase 1	2014-05-01	The primary objective of this research study is to test the hypothesis that late sodium current blocking drugs (mexiletine or lidocaine) can attenuate the effect of hERG potassium channel blocking drugs (dofetilide) on ventricular repolarization (QTc) by shortening early repolarization (J-Tpeakc). The secondary object is to assess the ability of calcium channel block (diltiazem) to reduce the QTc prolongation associated with hERG block (moxifloxacin).

Clinical Trial Conditions for MEXITIL

Condition Name

Condition Name for MEXITIL
Intervention	Trials
Sporadic Amyotrophic Lateral Sclerosis	2
Drug-induced QT Prolongation	1
Non Dystrophic Myotonia	1
Pharmacodynamics	1

Condition MeSH

Condition MeSH for MEXITIL
Intervention	Trials
Sclerosis	2
Motor Neuron Disease	2
Amyotrophic Lateral Sclerosis	2
Long QT Syndrome	1

Clinical Trial Locations for MEXITIL

Trials by Country

Trials by Country for MEXITIL
Location	Trials
United States	18
Netherlands	1

Trials by US State

Trials by US State for MEXITIL
Location	Trials
Washington	2
Pennsylvania	2
New York	2
Massachusetts	2
California	2

Clinical Trial Progress for MEXITIL

Clinical Trial Phase

Clinical Trial Phase for MEXITIL
Clinical Trial Phase	Trials
Phase 2	3
Phase 1	1

Clinical Trial Status

Clinical Trial Status for MEXITIL
Clinical Trial Phase	Trials
Completed	4

Clinical Trial Sponsors for MEXITIL

Sponsor Name

Sponsor Name for MEXITIL
Sponsor	Trials
University of Washington	2
ZonMw: The Netherlands Organisation for Health Research and Development	1
Radboud University	1

Sponsor Type

Sponsor Type for MEXITIL
Sponsor	Trials
Other	6
U.S. Fed	1

Last updated: April 23, 2026

Clinical Trials Update and Market Projection for MEXITIL (Mexiletine)

Mexitil (mexiletine) is an oral class Ib antiarrhythmic. Commercial trajectory and clinical activity are shaped by mature use in ventricular arrhythmia management, limited contemporary pipeline expansion in the US, and geographies where mexiletine is still treated as an established therapy. Public clinical-trial and patent landscapes are dominated by legacy development history rather than active, late-stage registrational programs.

What clinical trials activity exists for MEXITIL (mexiletine) now?

Publicly visible trial activity for mexiletine is largely characterized by:

• Small, investigator-led studies focused on arrhythmia phenotypes (often ventricular) and/or pharmacodynamic endpoints
• Niche indications and repurposing work in patient subgroups (where mexiletine shows mechanistic rationale such as sodium-channel modulation)

A full “active trials” map with counts by phase, status, and endpoints requires a live registry pull (trial-by-trial). This response does not produce such a map because it would require querying a current clinical-trials database at the time of writing.

Clinical development posture (registrational vs. supportive)

Mexiletine’s current market use indicates a posture dominated by:

• Supportive clinical literature and label maintenance rather than ongoing phase III registrational programs
• Regulatory focus on safety, tolerability, and use in defined arrhythmia settings rather than new large outcome trials

This is consistent with mexiletine being an established generic product in multiple jurisdictions, where incremental clinical development is less likely to drive market authorization unless a new formulation or new indication is pursued.

What is the market structure for mexiletine (MEXITIL) by key drivers?

Mexiletine pricing and demand sit in the center of two dynamics:

• Generic competition in most major markets reduces brand-specific share unless the brand has strong formulary penetration
• Physician-driven, protocol-based use for ventricular arrhythmias ties utilization to guideline interpretation, hospital formularies, and electrophysiology practice patterns

Demand drivers

• Arrhythmia burden and electrophysiology referral volume: demand correlates with procedural access and cardiology/electrophysiology throughput
• Treatment algorithms for ventricular arrhythmias: mexiletine is used when sodium-channel blockade is relevant and when alternative antiarrhythmics are not suitable or have failed
• Safety tolerance profile: mexiletine’s GI and neurologic adverse-event patterns influence adherence and patient selection

Supply and pricing drivers

• Generic availability: drives lower average net prices and compresses brand revenue
• Formulary access: determines short-cycle demand at health-system level more than broad advertising
• Manufacturing continuity: stable supply is required due to chronic or intermittent use patterns

How does genericization affect the “MEXITIL” brand revenue outlook?

If “MEXITIL” refers to mexiletine marketed under the brand in any given country, the brand revenue outlook depends on:

• Whether the brand retains meaningful reimbursement and formulary placement
• Whether there is a defended patient segment (e.g., stable patients on a brand) offsetting generic switching

In markets with full generic penetration, brand share usually declines unless:

• payer policy explicitly favors the brand, or
• physicians maintain brand loyalty due to perceived tolerability differences

What market projection is supportable for mexiletine?

A quantitative forecast requires an identifiable baseline (current unit sales or value, channel mix, geography, and price net of rebates). Without a baseline dataset, the only defensible projection is scenario-based directional guidance:

Base-case direction

• Low-to-mid single-digit value growth or flat value over the near term is typical for established generics under stable demand, driven by population trends and modest price declines leveling off.
• Volume may be stable to modestly up where electrophysiology referrals grow faster than discontinuation.

Downside case

• Continued price pressure as additional generics or discounts enter
• Protocol substitution if other antiarrhythmics or ablation strategies displace medication use

Upside case

• Formulary expansion in targeted geographies or health systems
• New clinical evidence that strengthens guideline positioning in specific ventricular arrhythmia subtypes

What patent landscape is most likely to matter for mexiletine (MEXITIL)?

Mexiletine is not a new molecule in commercial terms, and the near-term competitive landscape is generally dominated by:

• Expired composition-of-matter protection
• Residual patent value from manufacturing process, specific polymorph/formulation, or packaging only where such patents exist in specific jurisdictions and remain in force

A true patent-based projection requires a jurisdiction-by-jurisdiction claim-term matrix (filing, priority, expiration, and exclusivity events). This response does not generate that matrix, because doing so without verified data would create false precision.

Which clinical endpoints and tolerability signals matter commercially?

Commercial uptake in arrhythmia drugs hinges on:

• Effect on ventricular arrhythmia burden (measured via device data, arrhythmia episodes, or rhythm monitoring)
• Safety/tolerability that supports sustained prescribing:
  • neurologic effects (paresthesias, dizziness, tremor)
  • GI intolerance
  • conduction effects (QRS widening concerns relevant to sodium-channel blockers)
• Drug-drug interaction management (cardiology practice patterns and concomitant therapies)

Even when mexiletine is not used as a first-line antiarrhythmic, prescribers care whether outcomes justify ongoing use in patients who already have comorbidities.

---

Key Takeaways

• Mexiletine (MEXITIL) is an established antiarrhythmic with clinical use dominated by supportive evidence rather than active late-stage registrational trials.
• Generic competition is the primary market-shaping force for brand-level economics across major markets.
• A defensible forecast is directional: expect stable-to-modest growth in volume but flat-to-low growth in value due to pricing pressure, unless formulary or evidence-driven positioning changes.
• Any credible long-range projection should be anchored to current net sales baseline and geography plus patent/formulation tail analysis by jurisdiction.

---

FAQs

1) Is MEXITIL (mexiletine) in active phase III clinical trials today?

Most visible mexiletine activity tends to be supportive or niche rather than broad phase III registrational programs for new indications, consistent with its established market status.

2) Does mexiletine have strong brand protection in major markets?

Mexiletine is widely commercialized as a generic, so brand-specific exclusivity is limited in most mature jurisdictions.

3) What drives mexiletine prescribing decisions?

Prescribing is driven by ventricular arrhythmia management protocols, patient-specific suitability for sodium-channel blockade, monitoring feasibility, and tolerability.

4) What are the key safety issues affecting market use?

The main commercial impact comes from GI and neurologic adverse effects and the need for careful attention to cardiac conduction in appropriate patients.

5) What would most likely change the market outlook for mexiletine?

A meaningful shift would require either new guideline-strengthening clinical outcomes for a specific ventricular arrhythmia subtype or improved formulation/access that reduces discontinuation and improves formulary adoption.

---

References

[1] FDA. Drug Approval Packages and Labels (Mexiletine, where applicable). U.S. Food and Drug Administration.
[2] EMA. EPAR and product information for mexiletine-containing products. European Medicines Agency.
[3] WHOCC. ATC classification for mexiletine. World Health Organization Collaborating Centre for Drug Statistics Methodology.
[4] ClinicalTrials.gov. Mexiletine (search results and trial records). National Library of Medicine.
[5] APA Citation database entries and guideline documents (cardiac arrhythmia guidance citing mexiletine). American Heart Association / ESC guideline publications.